CureLab Oncology Inc
CureLab Oncology Inc., based in Boston, MA, is a biotechnology company dedicated to developing innovative anti-cancer biologics aimed at extending the lives of oncology patients. Their lead product, Elenagen, is a plasmid circular DNA encoding gene p62 SQSTM1, which has shown promise in reversing tumor grade, enhancing anti-tumoral immune responses, and mitigating chronic inflammation.
The company has completed international Phase I and IIa clinical trials of Elenagen, demonstrating a high degree of safety and clinical benefits for participants. Following these successes, CureLab Oncology is now initiating Phase II clinical trials both outside and within the United States to further assess Elenagen's effectiveness.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.